Zoetis Receives a Hold from J.P. MorganBy Jason Carr
According to TipRanks.com, Schott is a 1-star analyst with an average return of -4.3% and a 36.7% success rate. Schott covers the Healthcare sector, focusing on stocks such as Endo International, Impax Laboratories, and Merck & Company.
Currently, the analyst consensus on Zoetis is Moderate Buy and the average price target is $57, representing a 13.6% upside.
In a report released today, Barclays also reiterated a Hold rating on the stock with a $49 price target.
Based on Zoetis’ latest earnings report from June 30, the company posted quarterly revenue of $1.21B and quarterly net profit of $224M. In comparison, last year the company earned revenue of $1.21B and had a net profit of $189M.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. Most recently, in September 2016, Michael Mccallister, a Director at ZTS bought 2,000 shares for a total of $102,680.
Zoetis, Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The company was founded in July 2012 and is headquartered in New York, NY.